The European Medicines Agency (EMA) has advised that the drug can be used together with diet and physical activity to help ...

The market feels uncertain for many investors, but this Vanguard ETF could be a good choice. Here's what to know.

According to 26 different analyst ratings, Novo (NYSE:NVO) has the highest target price of $168.39 which means it could more than double from the current levels if the optimistic scenario unfolds. A ...

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

Executives mingled with North Carolina leaders in the city of Wilson to ceremonially break ground on Johnson & Johnson’s ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

Vanguard FTSE Europe ETF (VGK) and Vanguard Total International Stock ETF (VXUS) are outperforming the S&P 500 in 2025.

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...